


Raiffeisen HealthCare Equities (R)

Current fund strategy

Raiffeisen HealthCare Equities (R) is an equity fund. With a global scope, it invests mainly in equities issued by companies which are active in the development, manufacturing or sales of products or services related to healthcare, medicine, pharmaceuticals or biotechnology. The fund management works to optimise the risk-return profile using additional active strategies. The Fund is particularly suitable for investors who wish to benefit from the long-term earnings potential of the healthcare sector and are aware of the related risks, ranging from elevated price volatility to possible loss of capital or unfavourable currency developments.

The fund is actively managed with reference to a benchmark. Such reference to a benchmark does not restrict the fund management's scope of action. The fund was actively managed with reference to a benchmark until 14.11.2021. Since 15.11.2021, the fund has been actively managed without reference to a benchmark (change of factors for determination of the fund's performance). Further information may be found in the prospectus or the information for investors pursuant to § 21 AIFMG.

Investor's risk tolerance




Lower risk

Higher risk

General fund information

Fund launch	Apr 18, 2001
Fund volume in mn	179,87
Accounting year	01.06. - 31.05.
Annual dividend payment	16.08.
Bloomberg-Ticker	ACTHLT
ISIN distribution (A)	AT0000714274
ISIN reinvested (T)	AT0000714282

Recommended holding period in years



Comments from fund management

The fund suffered a slight decline in October. In terms of the subsectors, pharmaceuticals turned in the best performance while biotechnology names lagged behind the market trend.

The diagnostics company Illumina was newly added to the fund during the period.

Health care companies' research and development expenditures are still higher than the level seen prior to the outbreak of the coronavirus pandemic. As a result, several interesting new drugs and devices will come onto the market in the medtech industry in the coming months. (15.10.2021)

Performance 5 years: Oct 28, 2016 - Oct 29, 2021



Source: Custodian Bank (Raiffeisen Bank International AG)

Performance by calendar years



Source: Custodian Bank (Raiffeisen Bank International AG)

Benchmark

MSCI World Health Care Net

Weighting in %

100,00

Raiffeisen KAG calculates performance based on the published fund price, using the OeKB methodology. For more details on the calculation, please see the next page.¹

The benchmark is presented without costs and is not directly investable.

Presentation in accordance with the benchmark used in the past, which may deviate from the benchmark reported. We can also provide you with more detailed information free of charge on request.

The management company may change the benchmark in the interests of the unitholders. The respective current benchmark will be shown in the Key Investor Information Document, the prospectus or in the information pursuant to § 21 of the Austrian Alternative Investment Fund Managers Act (AIFMG).


Each of the indices mentioned is a registered brand. The licensing party does not sponsor the fund, subsidize it, sell it or support it in any other way. Index calculation and index licensing of indices or index brands do not represent a recommendation to invest. The respective licensor is not liable to third parties for any errors in the index. For legal information regarding licensors, see www.rcm.at/lizenzgeberhinweise or www.rcm-international.com.

Raiffeisen HealthCare Equities (R)

10 largest positions (proportion of fund assets in %)

UNITEDHEALTH GROUP INC UNH	4,12
THERMO FISHER SCIENTIFIC INC TMO	3,84
ABBOTT LABORATORIES ABT	3,65
ROCHE HOLDING AG-GENUSSCHEIN ROG	3,63
ELI LILLY & CO LLY	3,14
DANAHER CORP DHR	3,12
ASTRAZENECA PLC AZN	3,04
NOVO NORDISK A/S-B NOVOB	2,68
JOHNSON & JOHNSON JNJ	2,64
MERCK & CO. INC. MRK	2,54

Structure by country of domicile (proportion of fund assets)



Share class information

	ISIN	Launch
ISIN distribution (A)	AT0000714274	Apr 18, 2001
ISIN reinvested (T)	AT0000714282	Apr 18, 2001
Ongoing charges (%) ²		2,25
of which: management fee (%)		2,00

The management company notes that the sales office can charge fees for the purchase and/or redemption of unit certificates.

Risk indicators

Volatility (% p. a., 3 years)	13,90
Sharpe Ratio (p. a., 3 years)	0,90
Maximum Drawdown (% , since inception)	-50,60

The fund exhibits elevated volatility, meaning that unit prices can move significantly higher or lower in short periods of time, and it is not possible to rule out loss of capital.

This is a marketing notice. All of the data and information have been collected and assessed with great care; the sources used are considered to be reliable. The information is current as of the time of update. No liability or guaranty can be assumed for the accuracy or completeness of the information.

The published prospectuses, information for investors pursuant to § 21 AIFMG, and customer information documents (Key Investor Information Documents) for the investment funds of Raiffeisen Kapitalanlage-Gesellschaft m.b.H. are available in German at www.rcm.at under the heading "Kurse & Dokumente" (and for some funds the customer information documents are additionally available in English) or, if the fund shares are sold abroad, in English (if applicable in German) or in your national language at www.rcm-international.com under the heading "Prices & Documents". A summary of investors rights is available in German and English under the following link: <https://www.rcm.at/corporategovernance>. Note that Raiffeisen Kapitalanlage-Gesellschaft m.b.H. may decide to terminate the arrangements for the distribution of the fund unit certificates outside the fund domicile country Austria.

¹ Raiffeisen KAG calculates performance based on the published fund price, using the OeKB methodology. Individual costs – such as transaction fees, the subscription fee, the redemption fee or custody charges of the investor – and taxes are not included in the performance calculation. These would reduce the performance if they were included. Past value is not a reliable indicator of the fund's future performance. Notice for investors with a different functional currency than the fund currency: We expressly point out that returns may rise or fall due to currency fluctuations.

² The „ongoing charges“ have been calculated on the basis of the figures as of 31.12.2020 including the previous 12-month period. The „ongoing charges“ include the management fee and all fees charged in the past year. Third-party transaction costs and performance-related fees are not included in the „ongoing charges“. The „ongoing charges“ may differ from year to year. Please refer to the „Expenses“ sub-item of the current annual fund report for precise details of the cost components included in the „ongoing charges“.